Stent with polymer coating containing amorphous rapamycin
A coated coronary stent, comprising a stainless steel sent framework coated with a primer layer of Parylene C, and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.
1. A coated coronary stent, comprising:
a stainless steel stent framework coated with a primer layer of Parylene C; and
a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating consists of polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.
2. The stent of claim 1 , wherein PBMA, PEVA and rapamycin are present in a ratio of about 1:1:1.
3. The stent of claim 1 , wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 1:1:1.
4. The stent of claim 1 , wherein said coating has a thickness of about 1 to about 30 microns.
5. The stent of claim 1 , wherein said coating is substantially free of solvent residue.
6. The stent of claim 1 , wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 50 C to about 60 C and a pressure below 1000 psig, whereby bulk properties and adhesion of the coating to said stent are improved without altering the quality of the rapamycin, PBMA or PEVA.
7. The stent of claim 1 , wherein said rapamycin-polymer coating covers substantially the entire surface of said stent framework.
8. The stent of claim 1 , wherein said rapamycin-polymer coating is substantially free of aggregated particles.